Dr. Jörg Reinhardt
Dr. Jörg Reinhardt is a member of the Helmholtz Association’s senate for the research field Health and Chairman of the Board of Directors of the Swiss pharmaceutical concern Novartis AG.
The pharmacist with a PhD from the University of Saarbrücken began his career in 1982 at Sandoz AG, which merged with Ciba-Geigy to form Novartis in 1996. At Sandoz, he worked in the field of research and development and became Head of Development in 1994. After the merger, Jörg Reinhardt was initially responsible for the company’s preclinical development and from 1999 onwards, as Head of Pharmaceutical Development, for the entire drug development. From 2006 – 2008 he was CEO of Novartis’ Vaccines and Diagnostics Division and in 2008 he became Chief Operating Officer of Novartis.
Since 2013, Jörg Reinhardt has been Chairman of the Board of Directors of the Swiss pharmaceutical company Novartis AG. He is also Chairman of the Research & Development Committee and Chairman of the Board of Trustees of the Novartis Foundation and the Board of Trustees of the Institute of Molecular and Clinical Ophthalmology Basel (IOB).
He is a non-executive member of the Board of Directors of Swiss Re in Switzerland and a member of the Advisory Panel of Temasek Singapore.
From 2010 to 2012 he was Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee. Jörg Reinhardt has been a board member of several companies, including Chairman of the Board of Trustees of the Genomics Institute of the Novartis Research Foundation in the USA, member of the Supervisory Board of MorphoSys AG in Germany and member of the Board of Directors of Lonza Group AG.